Tuesday, October 22, 2019
Time: 11am ET / 8am PT
Duration: 1 hour
What are the advantages for drug developers to choose advanced dosage forms for new molecules in the development pipelines? Or, are advanced dosage forms more suitable for expanding product portfolio with the existing molecules? How can innovators select the most suitable technologies to create these advanced dosage forms?
To answer these questions, FiercePharma and Catalent recently conducted a survey to understand the factors affecting innovators’ decision to choose an advanced dosage form. In this webinar, industry experts will present the survey results and share insights on how advanced dosage forms can address the patient and molecule needs.
Register for the webinar to learn about the tools and technologies for creating advanced dosage forms such as orally disintegrating tablets (ODTs), multi-particulates, and modified release formulations.
Key learnings include:
- How to choose the dosage form and technologies to meet patient and molecule needs
- Value of advanced dosage forms for new and existing molecules
- Understanding the tools and techniques for creating advanced dosage forms
Ralph Lipp, Ph.D.
President and CEO
Lipp Life Sciences LLC
Head of Product Development
Director of Formulation Research and Development